10108591Toxicity predictions of novel drugs in development across different age groups in children healthcareClosedCollaborative R&DInnovate UKConsoneAI is a biotech business focused on reducing the need for animal testing and developing safer drugs, quicker and more effectively by creating a software platform to predict toxicity adverse effects of new chemicals being considered for clinical development in children's treatment. Our platforms DioScor and DioNexus, predict toxicology values and physiological effects which are essential in the evaluation of new drugs by looking at the chemical structure. Currently, 60-million animals are tested to ensure these toxic effects are not dangerous to human health before the first clinical trials in human studies take place. DioScor and DioNexcus toxicity prediction will reduce the number of animal testing experiments by allowing the user to see the predicted toxicological effects of a drug across a range of animal species through to human allowing drug and clinical development to select the most effective animal study and drug molecule and put human drug safety at the centre of the decision making. The drug development process is difficult and lengthy, approximately 92% of all new drugs fail to reach the market. Animal testing is hugely expensive and crucial to provide safety data before new molecules progress to human trials, although there are some alternatives to animal testing this is not utilised or embraced. However, this process faces additional complexities, especially concerning children's medication development and clinical trials. Children, from infancy to adolescence, possess different hormones and enzymes, resulting in varied toxicity (side effects) of medications. About 40% of deaths in children under 5 years old are attributed to toxicity issues of their treatment. DioNexcus intervenes at each stage of the drug development process, meticulously evaluating the toxicological impact on various animal species and extrapolating these effects to understand their translation between species. Typically, the translation of toxicity data between animals and humans hovers between 43-63%. DioNexcus's predictive models serve as a transformative solution to this challenge. By minimizing reliance on extensive animal testing, DioNexcus refines drug development resources, focusing on molecules exhibiting the most promising translational data across species. This streamlines the drug development trajectory(time and cost) but also enhances drug safety for humans. Our business goal is to work with the drug development industry and global drug regulators to provide safe evidence to develop animal and clinical trials across adults and paediatrics. Ultimately bringing new drug treatments to market more efficiently, effectively and improve patient safety!